Thermo Fisher Scientific (TMO) Stock Forecast: Raised Guidance, M&A Strategy & 2026 Outlook
1 extracted signal · 0 resolved · 1 still active
Global News DailyIndependent analyst profile- Source published
- 25 Sept 2026, 12:13 UTC
- Recorded by Tahlil Plus
- 25 Sept 2026, 16:27 UTC

AI-generated source summary
The company demonstrates strong Q2 2026 performance with revenue growth of 10% year-over-year and adjusted EPS growth of 13%. Revenue reached $11.99 billion, while adjusted EPS was $6.03, exceeding the consensus estimate by 5.6%. The company achieved 5% organic growth. Management's 2026 guidance projects revenue between $47.4 and $48.19 billion, indicating 6-8% growth. The company is actively deploying capital through strategic acquisitions, such as Clario, to deepen ties in clinical trial data management, and divestitures, like the $1.075 billion sale of its microbiology business, to streamline operations. Additionally, $1 billion was allocated to share buybacks in Q2, signaling a strong commitment to shareholder value. Key structural drivers supporting long-term growth include bioproduction (GLP-1 revolution), AI-fueled semiconductor demand ($1T in capacity investments), and the aging population (1.2B people over 65 by 2035). The stock currently trades at a P/E of 35x, with analyst targets ranging from $600 (Bernstein, Hold) to $730 (UBS, Buy), and a neutral rating from Piper Sandler at $600. Key risks to monitor include currency headwinds impacting H2 2026 EPS by an estimated 5 cents, regional unevenness with slow growth in China, and macro factors like inflation and tariffs.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Live evaluation in progress
1 signal remains active.
Global News Daily
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
